[
  {
    "ts": null,
    "headline": "Jim Cramer Notes Eli Lilly (LLY) Stock is at a “Decent Level to Start a Position”",
    "summary": "We recently published a list of Jim Cramer Had These 21 Stocks on His Radar. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim Cramer discusses. A caller asked what Cramer’s thoughts on Eli Lilly and Company (NYSE:LLY) were, and he […]",
    "url": "https://finnhub.io/api/news?id=88e5d0865b581f1762271f77f6666d9416d39dfb2a8d56e24b2453f97f995d2c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748382870,
      "headline": "Jim Cramer Notes Eli Lilly (LLY) Stock is at a “Decent Level to Start a Position”",
      "id": 134722363,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published a list of Jim Cramer Had These 21 Stocks on His Radar. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim Cramer discusses. A caller asked what Cramer’s thoughts on Eli Lilly and Company (NYSE:LLY) were, and he […]",
      "url": "https://finnhub.io/api/news?id=88e5d0865b581f1762271f77f6666d9416d39dfb2a8d56e24b2453f97f995d2c"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Advance Late Afternoon",
    "summary": "Health care stocks rose late Tuesday afternoon, with the NYSE Health Care Index rising 1.5% and the",
    "url": "https://finnhub.io/api/news?id=b2ecce1ffadd74ff529e4232e0e71816080a3dd47e0288256cb3e7d53c6e88d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748376073,
      "headline": "Sector Update: Health Care Stocks Advance Late Afternoon",
      "id": 134715824,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks rose late Tuesday afternoon, with the NYSE Health Care Index rising 1.5% and the",
      "url": "https://finnhub.io/api/news?id=b2ecce1ffadd74ff529e4232e0e71816080a3dd47e0288256cb3e7d53c6e88d0"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Targets Pain Management Opportunity with SiteOne Therapeutics Acquisition",
    "summary": "Eli Lilly and Company (NYSE:LLY) is expanding its footprint into the non-opioid pain management market in pursuit of growth opportunities. On May 27, the company announced the inking of an agreement to acquire SiteOne therapeutics. The company is acquiring the private biotech company in a deal worth up to $1 billion in cash and milestone-based […]",
    "url": "https://finnhub.io/api/news?id=5168a1fbfe75ea0fb6c502af1175081877e06710574525f9627a6a446f641423",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748373907,
      "headline": "Eli Lilly Targets Pain Management Opportunity with SiteOne Therapeutics Acquisition",
      "id": 134715826,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is expanding its footprint into the non-opioid pain management market in pursuit of growth opportunities. On May 27, the company announced the inking of an agreement to acquire SiteOne therapeutics. The company is acquiring the private biotech company in a deal worth up to $1 billion in cash and milestone-based […]",
      "url": "https://finnhub.io/api/news?id=5168a1fbfe75ea0fb6c502af1175081877e06710574525f9627a6a446f641423"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Strikes up to $1 Billion Deal for SiteOne Therapeutics in Bid to Grow Pain Drug Pipeline",
    "summary": "Eli Lilly (LLY) has agreed to acquire privately held SiteOne Therapeutics in a deal worth up to $1 b",
    "url": "https://finnhub.io/api/news?id=e3e028cf2c81d5dae278dd4057b4ec25fa14df526ac5d10908a23ffcb1ffcb80",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748373121,
      "headline": "Eli Lilly Strikes up to $1 Billion Deal for SiteOne Therapeutics in Bid to Grow Pain Drug Pipeline",
      "id": 134715828,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) has agreed to acquire privately held SiteOne Therapeutics in a deal worth up to $1 b",
      "url": "https://finnhub.io/api/news?id=e3e028cf2c81d5dae278dd4057b4ec25fa14df526ac5d10908a23ffcb1ffcb80"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to expand pain pipeline with $1bn SiteOne buyout",
    "summary": "The deal prepares for a pain treatment market rivalry with Vertex Pharmaceuticals as the industry starts to move away from opioids.",
    "url": "https://finnhub.io/api/news?id=ae5a2fccb2f40bf1351d0b131e6ce7ddc8021726efcb8617fe0d53171311a719",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748366758,
      "headline": "Eli Lilly to expand pain pipeline with $1bn SiteOne buyout",
      "id": 134715829,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The deal prepares for a pain treatment market rivalry with Vertex Pharmaceuticals as the industry starts to move away from opioids.",
      "url": "https://finnhub.io/api/news?id=ae5a2fccb2f40bf1351d0b131e6ce7ddc8021726efcb8617fe0d53171311a719"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock rises Tuesday, still underperforms market",
    "summary": "Eli Lilly & Co. stock rises Tuesday, still underperforms market",
    "url": "https://finnhub.io/api/news?id=6f35f05caf57d631671672df23d9ec31ddad18131b3fb88c341b3f95d8e24110",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748363460,
      "headline": "Eli Lilly & Co. stock rises Tuesday, still underperforms market",
      "id": 134716557,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock rises Tuesday, still underperforms market",
      "url": "https://finnhub.io/api/news?id=6f35f05caf57d631671672df23d9ec31ddad18131b3fb88c341b3f95d8e24110"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly expands pain pipeline with acquisition of SiteOne Therapeutics",
    "summary": "Investing.com -- Eli Lilly and Company (NYSE:LLY) is expanding its neuroscience pipeline through the acquisition of SiteOne Therapeutics in a deal worth up to $1 billion, deepening its bet on non-opioid pain treatments. The centerpiece of the acquisition is STC-004, a Phase 2-ready Nav1.8 inhibitor that could offer significant relief to patients suffering from chronic pain without the risks associated with addictive medications.",
    "url": "https://finnhub.io/api/news?id=b0cfb548ee241c488aab5036ff8466622a5c3974f835c9f867f8a087c9a4a06f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748357974,
      "headline": "Eli Lilly expands pain pipeline with acquisition of SiteOne Therapeutics",
      "id": 134715831,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Eli Lilly and Company (NYSE:LLY) is expanding its neuroscience pipeline through the acquisition of SiteOne Therapeutics in a deal worth up to $1 billion, deepening its bet on non-opioid pain treatments. The centerpiece of the acquisition is STC-004, a Phase 2-ready Nav1.8 inhibitor that could offer significant relief to patients suffering from chronic pain without the risks associated with addictive medications.",
      "url": "https://finnhub.io/api/news?id=b0cfb548ee241c488aab5036ff8466622a5c3974f835c9f867f8a087c9a4a06f"
    }
  },
  {
    "ts": null,
    "headline": "What’s the Price Outlook for Weight-Loss Drugs?",
    "summary": "The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some questions consumers have.",
    "url": "https://finnhub.io/api/news?id=54bbb10ab47d7f78e14e96e3038df47c4ff2c99ad685ba9c8bfa1b3f5b682007",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748354400,
      "headline": "What’s the Price Outlook for Weight-Loss Drugs?",
      "id": 134715834,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some questions consumers have.",
      "url": "https://finnhub.io/api/news?id=54bbb10ab47d7f78e14e96e3038df47c4ff2c99ad685ba9c8bfa1b3f5b682007"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics",
    "summary": "Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. (\"SiteOne\"), a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, today announced a definitive agreement for Lilly to acquire SiteOne.",
    "url": "https://finnhub.io/api/news?id=c52596aeb103048959081f70da342de9a1fc909844e5b863280648c97319360b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748354400,
      "headline": "Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics",
      "id": 134715833,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, Inc. (\"SiteOne\"), a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, today announced a definitive agreement for Lilly to acquire SiteOne.",
      "url": "https://finnhub.io/api/news?id=c52596aeb103048959081f70da342de9a1fc909844e5b863280648c97319360b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=660556cf1bf81da9260d195208054b11aa5a1d7cc1b1340c56f551567a081694",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748350813,
      "headline": "Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know",
      "id": 134715836,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=660556cf1bf81da9260d195208054b11aa5a1d7cc1b1340c56f551567a081694"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company agreed to acquire SiteOne Therapeutics, Inc. for $1 billion.",
    "summary": "Eli Lilly and Company agreed to acquire SiteOne Therapeutics, Inc. for $1 billion on May 27, 2025. As part of consideration SiteOne shareholders could receive up to $1.0 billion in cash, inclusive of...",
    "url": "https://finnhub.io/api/news?id=8b148948db7b06f1c490c8749b3b7efb2164c7dbc7deb1d2792be8a36502a039",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748349324,
      "headline": "Eli Lilly and Company agreed to acquire SiteOne Therapeutics, Inc. for $1 billion.",
      "id": 134709682,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly and Company agreed to acquire SiteOne Therapeutics, Inc. for $1 billion on May 27, 2025. As part of consideration SiteOne shareholders could receive up to $1.0 billion in cash, inclusive of...",
      "url": "https://finnhub.io/api/news?id=8b148948db7b06f1c490c8749b3b7efb2164c7dbc7deb1d2792be8a36502a039"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to buy pain drug developer SiteOne, challenging Vertex",
    "summary": "The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.",
    "url": "https://finnhub.io/api/news?id=8766df09f2568c37d9ba5fc6e40ab96aa9166f926ac8e3c7d777c1af278aea56",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748349000,
      "headline": "Lilly to buy pain drug developer SiteOne, challenging Vertex",
      "id": 134715838,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.",
      "url": "https://finnhub.io/api/news?id=8766df09f2568c37d9ba5fc6e40ab96aa9166f926ac8e3c7d777c1af278aea56"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to buy SiteOne for $1 billion with eye on non-opioid pain drug",
    "summary": "Eli Lilly will buy privatelyheld SiteOne Therapeutics in a deal worth as much as $1 billion,the companies said on Tuesday, giving the drugmaker access to anexperimental non-opioid pain medicine. ...",
    "url": "https://finnhub.io/api/news?id=b475a329e4b49d7cfbd6d7874fe27001067fb2091618c08c094c5ff95ce60ac1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748348884,
      "headline": "Eli Lilly to buy SiteOne for $1 billion with eye on non-opioid pain drug",
      "id": 134709629,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly will buy privatelyheld SiteOne Therapeutics in a deal worth as much as $1 billion,the companies said on Tuesday, giving the drugmaker access to anexperimental non-opioid pain medicine. ...",
      "url": "https://finnhub.io/api/news?id=b475a329e4b49d7cfbd6d7874fe27001067fb2091618c08c094c5ff95ce60ac1"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to Acquire SiteOne Therapeutics for Up to $1 Billion",
    "summary": "By Dean Seal Eli Lilly has agreed to acquire the pain-treatment company SiteOne Therapeutics for up to $1 billion in cash. The drug company said Tuesday that the acquisition includes...",
    "url": "https://finnhub.io/api/news?id=efa139c35209b96fec5a1bcc65cb446a66639a0daf96bf50e5cbd1973c484fa7",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748342534,
      "headline": "Eli Lilly to Acquire SiteOne Therapeutics for Up to $1 Billion",
      "id": 134708984,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "By Dean Seal Eli Lilly has agreed to acquire the pain-treatment company SiteOne Therapeutics for up to $1 billion in cash. The drug company said Tuesday that the acquisition includes...",
      "url": "https://finnhub.io/api/news?id=efa139c35209b96fec5a1bcc65cb446a66639a0daf96bf50e5cbd1973c484fa7"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to buy privately held SiteOne in deal worth up to $1 billion",
    "summary": "Eli Lilly will buy privatelyheld SiteOne Therapeutics in a deal worth as much as $1 billion,the companies said on Tuesday, giving the drugmaker access to anexperimental non-opioid pain medicine. ...",
    "url": "https://finnhub.io/api/news?id=1be49b6053dc77d61c0e7a77383884f27dceabf2de91181d9fb61f434e6c1ed4",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748341688,
      "headline": "Eli Lilly to buy privately held SiteOne in deal worth up to $1 billion",
      "id": 134708892,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly will buy privatelyheld SiteOne Therapeutics in a deal worth as much as $1 billion,the companies said on Tuesday, giving the drugmaker access to anexperimental non-opioid pain medicine. ...",
      "url": "https://finnhub.io/api/news?id=1be49b6053dc77d61c0e7a77383884f27dceabf2de91181d9fb61f434e6c1ed4"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to acquire privately held SiteOne",
    "summary": "Eli Lilly will acquire privately held SiteOne Therapeutics, the companies said on Tuesday, giving the drugmaker access to an experimental non-opioid pain drug. ...",
    "url": "https://finnhub.io/api/news?id=493e53a4be2dec9df190734d2aad3cc0342220ea2ee36cd0d70fdb412f2a439c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748340610,
      "headline": "Eli Lilly to acquire privately held SiteOne",
      "id": 134708838,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly will acquire privately held SiteOne Therapeutics, the companies said on Tuesday, giving the drugmaker access to an experimental non-opioid pain drug. ...",
      "url": "https://finnhub.io/api/news?id=493e53a4be2dec9df190734d2aad3cc0342220ea2ee36cd0d70fdb412f2a439c"
    }
  },
  {
    "ts": null,
    "headline": "Investment Case For Eli Lilly Still Weak Despite Novo Nordisk's Struggle",
    "summary": "Investment Case For Eli Lilly Still Weak Despite Novo Nordisk's Struggle",
    "url": "https://finnhub.io/api/news?id=e12fa86a6878f64b4a2126de0e7c7be592abddb3d6a7289ac9b7ea0bc0eb7d59",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748339831,
      "headline": "Investment Case For Eli Lilly Still Weak Despite Novo Nordisk's Struggle",
      "id": 134708853,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e12fa86a6878f64b4a2126de0e7c7be592abddb3d6a7289ac9b7ea0bc0eb7d59"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics: Buy It For The Future And Ignore The Noise",
    "summary": "Viking Therapeutics: Buy It For The Future And Ignore The Noise",
    "url": "https://finnhub.io/api/news?id=775c3709e392fdfa3d0b9321e9163a4d42e71a62639d4c48f0819fdfab765624",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748336400,
      "headline": "Viking Therapeutics: Buy It For The Future And Ignore The Noise",
      "id": 134708461,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=775c3709e392fdfa3d0b9321e9163a4d42e71a62639d4c48f0819fdfab765624"
    }
  },
  {
    "ts": null,
    "headline": "Here's How the Pharmaceutical Import Tariffs Could Affect Eli Lilly",
    "summary": "Tariffs on pharmaceutical imports could hurt Lilly, especially with its dependence on products made in Ireland.  The president's most favored nation drug pricing could also be problematic for Lilly, but perhaps not as much as feared.",
    "url": "https://finnhub.io/api/news?id=33c10547982bd9c475073374244a2bc8d93a3e792eaa2ea46ff74ad2d0966771",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748335440,
      "headline": "Here's How the Pharmaceutical Import Tariffs Could Affect Eli Lilly",
      "id": 134715839,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Tariffs on pharmaceutical imports could hurt Lilly, especially with its dependence on products made in Ireland.  The president's most favored nation drug pricing could also be problematic for Lilly, but perhaps not as much as feared.",
      "url": "https://finnhub.io/api/news?id=33c10547982bd9c475073374244a2bc8d93a3e792eaa2ea46ff74ad2d0966771"
    }
  },
  {
    "ts": null,
    "headline": "Prediction: These 2 Stocks Will Beat the Market in the Next Decade",
    "summary": "Eli Lilly and DexCom have been market-beaters over the past decade.  Eli Lilly could ride the wave of a strong lineup and deep pipeline, especially in weight management.  DexCom's devices are valuable to diabetes patients, but there's still a significant untapped opportunity.",
    "url": "https://finnhub.io/api/news?id=f5d89a50096f9abd7606e6f598cc8b8f99b7eed12ea63bad23c6c7bea471ab5f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748331960,
      "headline": "Prediction: These 2 Stocks Will Beat the Market in the Next Decade",
      "id": 134715841,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and DexCom have been market-beaters over the past decade.  Eli Lilly could ride the wave of a strong lineup and deep pipeline, especially in weight management.  DexCom's devices are valuable to diabetes patients, but there's still a significant untapped opportunity.",
      "url": "https://finnhub.io/api/news?id=f5d89a50096f9abd7606e6f598cc8b8f99b7eed12ea63bad23c6c7bea471ab5f"
    }
  }
]